Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.

@article{Manca2011InductionOA,
  title={Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.},
  author={Antonella Manca and Maria Cristina Sini and Francesco Izzo and Paolo Antonio Ascierto and Fabiana Tatangelo and Gerardo Botti and Giusy Gentilcore and Marilena Capone and Nicola Mozzillo and Carla Rozzo and Antonio Cossu and Francesco Tanda and Giuseppe Palmieri},
  journal={Oncology reports},
  year={2011},
  volume={25 6},
  pages={
          1495-502
        }
}
Arginine deiminase (ADI), an arginine-degrading enzyme, has been used in the treatment of tumours sensitive to arginine deprivation, such as malignant melanoma (MM) and hepatocellular carcinoma (HCC). Endogenous production of arginine is mainly dependent on activity of ornithine transcarbamylase (OTC) and argininosuccinate synthetase (ASS) enzymes. We evaluated the effect of ADI treatment on OTC and ASS expression in a series of melanoma cell lines. Twenty-five primary melanoma cell lines and… 
View on PubMed
spandidos-publications.com
23 Citations
Highly Influential Citations
2
Background Citations
7
Methods Citations
1
Results Citations
1

Figures from this paper

23 Citations

Citation Type

Citation Type

L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.
TLDR
L-arginine enhanced ADI-induced inhibited cell growth through expression of NF-κBp65 and p53 in a dose-dependent manner, and enhanced the effects of ADI treatment, when combined with different concentrations of L-Arginine.
Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
TLDR
The combination of arginine deprivation and cisplatin function in concert to kill tumor cells which do not express ASS without added toxicity to normal cells.
Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes
TLDR
It is shown that colorectal cancers (CRCs) display negligible expression of OTC and, in subset of cases, ASS1 proteins, and arginase antagonizes chemotherapeutic drugs oxaliplatin and 5-fluorouracil (5-FU), whereas ADI-PEG20 synergizes with oxali platin in ASS1-negative cell lines and appears to interact with 5- fluorourACil independently of ASS1 status.
Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability
TLDR
It is concluded that the novel combinatorial targeting strategy of metabolic-chemo-radiotherapy has great potential for the treatment of malignancies with inducible ASS1 expression.
Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
TLDR
The combination of PAN and ADI-PEG20 is a rational translational therapeutic strategy for treating ASS1-low PDAC tumors through synergistic induction of DNA damage.
Arginine dependence of tumor cells: targeting a chink in cancer’s armor
TLDR
Arginine, one among the 20 most common natural amino acids, has a pivotal role in cellular physiology as it is being involved in numerous cellular metabolic and signaling pathways and if successful will potentially be advanced as anti-cancer modalities.
Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines
TLDR
Results indicate that the ASS1 protein is required for cell migration in gastric cancer cell lines, and the sensitivity of tumor cells to arginine depletion was determined in Gastric cancer cells.
Recombinant Bacillus caldovelox Arginase Mutant (BCA-M) Induces Apoptosis, Autophagy, Cell Cycle Arrest and Growth Inhibition in Human Cervical Cancer Cells
TLDR
Mechanistic studies showed that BCA-M inhibited the growth of human cervical cancer cells by inducing apoptosis and cell cycle arrest at S and/or G2/M phases, while the growth inhibitory effects of B CA-M could be enhanced synergistically by its combination to the autophagy inhibitor, chloroquine (CQ).
Metabolic pathways of L-arginine and therapeutic consequences in tumors.
Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells
TLDR
It is hypothesize that HuArgI (Co)-PEG5000 in combination with L-citrulline supplementation may be an attractive therapeutic agent for some argininosuccinate synthetase-deficient tumors.
...
1
2
3
...

References

SHOWING 1-10 OF 29 REFERENCES
Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase
TLDR
Examination of the expression levels of ASS in various cancer cells found that it is low in renal cell carcinoma (RCC) cells, rendering the cells highly sensitive to arginine deprivation by ADI treatment, suggesting that arginin deprivation byADI could provide a beneficial strategy for the treatment of RCC in ways of inhibitions of arginines availability and neovascularization.
Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase
TLDR
Findings suggest that arginine deprivation by ADI could provide a beneficial strategy for the treatment of pancreatic cancer, a malignancy in which new therapy is desperately needed.
High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro
TLDR
It is demonstrated that human melanoma cells were highly sensitive to the growth inhibitory activity of AD and that it might be possible to develop agents with strong AD activity for chemotherapeutic use for human melanomas in vivo.
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
TLDR
The prospects for novel approaches in the prevention, diagnosis and treatment of malignant disease based on ASS1 pathophysiology and its rate‐limiting product, arginine are examined.
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
TLDR
Data indicate that sensitivity of melanoma and HCC is due to the absence of argininosuccinate synthetase in these cells and that an effective formulation of ADI, which causes a sustained decrease in arginine, may be a useful treatment forArginine auxotrophic tumors including melanomas and H CC.
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.
TLDR
It is found that arginine deprivation inhibits mTOR signaling but leads to activation of MEK and ERK with no changes in BRAF, which most likely lead to autophagy, a possible mechanism to survive by recycling intracellularArginine.
Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
TLDR
Direct evidence that recombinant human arginase (rhArg) inhibits ASS-positive HCCs is provided and the growth of the OTC-deficient Hep3B tumor cells (ASS-positive and ADI-resistant) in mice was inhibited by treatment with rhArg-peg(5,000mw), which is active alone and is synergistic in combination with 5-fluorouracil.
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers
TLDR
The purpose of these experiments was to determine the frequency of ASS deficiency and arginine auxotrophy in a variety of human malignant tumors.
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma.
TLDR
Pgylated ADI is a promising drug that capitalizes on a significant enzymatic deficiency in HCC and is safe, well tolerated, and may benefit patients with unresectable HCC.
...
1
2
3
...